In Vitro Diagnostics Global Market Report 2024

The insurance (providers, brokers and re-insurers) market size has grown strongly in recent years. It will grow from $8,277.04 billion in 2023 to $8,898.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%.

The growth observed in the historical period can be attributed to various factors, including the demand for risk management, regulatory necessities, population expansion, and the impact of catastrophic events.

The insurance (providers, brokers and re-insurers) market size is expected to see strong growth in the next few years. It will grow to $11,853.99 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%.

The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.

The in-vitro diagnostics devices and equipment market research report is one of a series of new reports that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with an in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticipated growth in the forecast period can be linked to several factors, including the emergence of new risks, the acceleration of digital transformation, demographic shifts, a sustained focus on sustainability and ESG (Environmental, Social, and Governance), as well as the ongoing effects of globalization and trade. Major trends expected during this period encompass usage-based insurance (UBI), innovation in Insurtech, parametric insurance, cyber insurance, and the emergence of peer-to-peer (P2P) insurance.

The growing adoption of self-administered test kits is set to fuel the expansion of the in vitro diagnostics market in the forthcoming years. These kits are designed for self-use, eliminating the necessity for medical professionals or trained individuals to conduct the tests, allowing people to perform diagnostic evaluations at their residences. This increased accessibility and convenience could potentially result in a higher demand for testing, especially for conditions that may have previously gone undetected. For example, statistics from the Centers for Disease Control and Prevention in April 2022 exhibited a significant surge in the use of at-home COVID-19 tests among adults aged 18 and older in the United States. Comparing the Delta-dominant period (August to December 2021) to the Omicron-dominant period (December to March 2022), there was a notable increase in at-home test utilization among respondents experiencing symptoms resembling COVID-19, rising from 5.7% to 20.1%. Hence, the increasing adoption of self-administered test kits is anticipated to be a driving factor in the growth of the in vitro diagnostics market.

The projected rise in the prevalence of cancer is expected to drive the expansion of the in vitro diagnostics market. Cancer comprises a wide array of over 100 diseases that can manifest in various parts of the body, characterized by the uncontrolled proliferation and dissemination of cells. In vitro diagnostics (IVDs) encompass tests or medical devices that analyze samples obtained from the human body, providing vital information for the screening, diagnosis, and treatment of cancer. For instance, data from the American Cancer Society in January 2023 indicated that the number of cancer cases increased to 1,958,310 in 2023, marking a 3.16% growth from 1,898,160 in 2021. Consequently, the anticipated rise in cancer prevalence is set to drive the growth of the in vitro diagnostics market.

Key companies in the in vitro diagnostics market are focusing on the development of innovative products to drive their market growth, such as the Cobas pulse system. This system is a professional blood glucose management solution equipped with mobile digital health capabilities to enhance patient care. For example, in January 2022, Roche Diagnostics, a US-based company specializing in innovative products and services addressing disease prevention, diagnosis, monitoring, screening, and treatment, introduced the Cobas pulse system. This portable device comprises an automated glucose test strip reader, a camera, and a touchscreen for capturing additional diagnostic data. Its user-friendly interface is designed for seamless integration, providing convenient functionalities that optimize processes, save time, and improve operational workflows.

Prominent companies in the in vitro diagnostics market are embracing artificial intelligence (AI) technology, such as LooK SPOT, to augment the precision and effectiveness of testing procedures. LooK SPOT serves as an in vitro diagnostic COVID-19 test integrated with AI, utilizing AI algorithms and machine learning techniques to enhance the accuracy and efficiency of the testing process. For example, in February 2021, Yas Pharmaceutical Co., an Iran-based pharmaceutical firm, in collaboration with Pure Health Company, a US-based healthcare organization, and Laipac Technology Inc., a Canada-based company specializing in IoT-integrated smart devices, launched LooK SPOT, an AI-powered rapid COVID-19 antigen test in the UAE. This test entails collecting a nasal sample from an inch within the nostril, and the cassette is then linked to a smartphone with the LooK Pass app installed. The app uses AI technology to scan the cassette and determine whether the test result is positive or negative. The incorporation of AI in the LooK SPOT test significantly improves accuracy by reducing the likelihood of human error. The AI algorithm has the capability to identify color signals even in low-positive cases, making it more sensitive than other antigen tests.

Major companies operating in the in vitro diagnostics market include Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.

North America was the largest region in the global in-vitro diagnostics market in 2023. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the in vitro diagnostics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa

The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.